You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Actinium Pharmaceuticals' 2025 Annual Report describes it as a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies, highlighting lead candidate ATNM-400's pre-clinical activity across mCRPC, NSCLC, and breast cancer.
Actinium Pharmaceuticals' proxy statement sets a November 25, 2026 annual meeting to elect David Nicholson and Richard I. Steinhart as Class I directors, ratify CBIZ CPAs P.C. as auditor for fiscal 2026, and hold an advisory vote on named executive officer compensation.
On October 14, 2026, Actinium Pharmaceuticals, Inc. appointed Matt David, M.D. as Chief Financial Officer and principal financial officer. His offer includes a $450,000 annual base salary, 40% target bonus, $150,000 sign-on bonus, an option for 250,000 shares and 325,000 restricted stock units.
